- Bora Biologics has opened a $30 million expansion of its FDA-approved manufacturing facility in San Diego.
- The expansion adds upstream and downstream GMP capabilities, including up to four 2,000-liter bioreactors, to support biologics contract manufacturing from late-stage development to commercial supply.
Bora Biologics has opened its expanded FDA-approved manufacturing facility in San Diego following a $30 million investment aimed at increasing biologics manufacturing capacity. The company marked the opening with a ribbon-cutting ceremony attended by company leadership, employees, community partners, and San Diego Mayor Todd Gloria.
The expansion adds state-of-the-art upstream and downstream GMP processing capabilities to meet growing demand for 2,000-liter scale single-use biologics manufacturing. The site now includes two to four 2,000-liter bioreactors, corresponding seed trains, and advanced downstream processing equipment, increasing the company’s U.S.-based capacity for microbial- and mammalian-expressed therapeutics.
“This expansion marks an important milestone for Bora Biologics and reflects our commitment to supporting the development and manufacture of high-quality, life-saving biologics. The expanded GMP facility strengthens the company’s ability to support U.S.-based programs moving from late-stage development into commercial supply.”
Stephen Lam, CEO of Bora Biologics
The San Diego site expansion enables the CDMO to offer 2,000-liter commercial manufacturing capacity supported by infrastructure and operational expertise designed for modern, high-titer cell culture processes. The facility is intended to serve both local and global biotech customers.
With the expanded site now operational, Bora Biologics is positioned to support end-to-end biologics development and contract manufacturing, spanning early development through commercial supply, while contributing to ongoing growth in the San Diego life sciences ecosystem.
